Tumour necrosis factor- α and transforming growth factor- β are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization

Abstract

Recent in vitro and in vitro studies have demonstrated a wide spectrum of biologic activities of cytokines in the pathogenesis and progression of malignancy. Tumour necrosis factor alpha (TNF-α) and transforming growth factor beta (TGF-β) have emerged as two of the many host-derived mediators that seem to interfere with both antiproliferative and tumorigenic effects in malignant tumours including lung cancer. However, their association with tumour prognosis or prognostic factors has not yet been completely clarified. In this study, we assessed TNF-α and TGF-β mRNA expression by RT-PCR technique in 61 NSCLC samples, demonstrating the presence of TNF-α and TGF-β mRNA in 55.74% and 45.9% of cases, respectively. We also evaluated the expression of the two distinct transmembrane TNF receptors. TNFR-I and TNFR-II, with a PCR-positive signal in 70.49% and 65.57% of cases, respectively. In 49 of the 61 cases, we evaluated the prognostic impact of the two growth-inhibiting factors using the Kaplan–Meier analysis. In the univariate analysis patients without nodal metastatic involvement (P = 0.02), less advanced tumour stage (P = 0.02) or TNF-α and TGF-β positive cancers (P = 0.01 and P = 0.03) showed a favourable prognosis in terms of overall survival. Since our previous studies demonstrated a significant association between NSCLC behaviour, neoangiogenesis and bcl -2 expression, we investigated the putative relation between TNF-α and TGF-β on the one hand, and vascular count (as a measure of tumour angiogenesis) and bcl -2 protein expression, on the other hand. Our results showed a significant direct association between TNF-α and bcl -2 (P = 0.05) and an inverse association between TNF-α and microvessel count (P = 0.03). Moreover, as previously demonstrated, we observed a significant inverse correlation between bcl -2 protein expression and vascular count (P = 0.05), suggesting that the favourable effect of TNF-α on clinical outcome may be related to a bcl -2-mediated low neovascular development. © 2000 Cancer Research Campaign

Change history

  • 16 November 2011

    This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication

References

  1. American Joint Committee on Cancer (1992). Manual for a staging of Cancer, 115–122

  2. Auvinen P, Lipponen P, Johansson R and Syrjanen K (1995) Prognostic significance of TGF-β1 and TGF-β2 expression in female breast cancer. Anticancer Res 15: 2627–2632

  3. Blood CH and Zetter BR (1990) Tumor interactions with the vasculature: angiogenesis and tumour metastasis. Biochem Biophys Acta 1032: 89–118

  4. Boldrini L, Calcinai A, Silvestri V, Basolo F, Lucchi M, Mussi A, Angeletti CA, Bevilacqua G and Fontanini G (1999) Quantitation by competitive PCR assay of vascular endothelial growth factor in non-small cell lung carcinomas. International Journal of Oncology 14: 161–168

  5. Cordell JL, Falini B, Erber WN, Abdulaziz Z, Macdonald S, Pulford KAF, Stein H and Mason DY (1984) Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complex). J Histochem Cytochem 32: 219–222

  6. Derynk R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, Roberts AB, Sporn NB and Baum M (1985) Human transforming growth factor-beta, complementary DNA sequence and expression in normal and transformed cells. Nature 316: 701–705

  7. Fajardo LF, Kwan HH, Kowalski J, Prionas SD and Allison AC (1992) Dual role of tumour necrosis factor a angiogenesis. Am J Pathol 140: 539–544

  8. Fajardo LF, Prionas SD, Kwan HH, Kowalski J and Allison AC (1996) Transforming growth factor b1 induces angiogenesis in vitro with a threshold pattern. Lab Invest 74: 600–608

  9. Fontanini G, Lucchi M, Vignati S, Mussi A, Ciardiello F, De Laurentiis M, De Placido S, Basolo F, Angeletti CA and Bevilacqua G (1997) Angiogenesis as a prognostic indicator of survival in non-small cell lung carcinoma: a prospective study. J Natl Cancer Inst 89: 881–886

  10. Fontanini G, Boldrini L, Vignati S, Chinè S, Basolo F, Silvestri V, Lucchi M, Mussi A, Angeletti CA and Bevilacqua G (1998) Bcl-2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma. Eur J Cancer 34: 718–723

  11. Fox SB, Westwood M, Moghaddam A, Comley M, Turley H, Whitehouse RM, Bicknell R, Gatter KC and Harris AL (1996) The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br J Cancer 73: 275–280

  12. Hong WS, Jett JR, Sasaki Y, Takahashi H, Nakano H, Nakagawa K, Hoshi A and Saijo N (1987) Colony inhibitory effect of recombinant human tumour necrosis factor (rH-TNF) and/or recombinant human interferon (rH-IFN)-alpha, -beta, and -gamma on human lung cancer cell lines. Jpn J Clin Oncol 17: 49–55

  13. Kemeny N, Childs B, Larchian W, Rosado K and Kelsen D (1990) A phase II trial of recombinant tumour necrosis factor in patients with advanced colorectal carcinoma. Cancer 66: 659–663

  14. Koukourakis MI, Giatromanolaki A, O'Byrne KJ, Whitehouse RM, Talbot DC, Gatter KC and Adrian Harris (1997) Potential role of bcl-2 as a suppressor of tumour angiogenesis in non small-cell lung cancer. Int J Cancer 74: 565–570

  15. Heim ME, Siegmund R, Illiger HJ, Klee M, Rieche K, Berdel WE and Edler L (1990) Tumour necrosis factor in advanced colorectal cancer: a phase II study. A trial of phase I/II study group of the Association for Medical Oncology of the German Cancer Society. Onkologie 13: 444–447

  16. Hennet T, Bertoni G, Richter C and Peterhans E (1993) Expression of BCL-2 protein enhances the survival of Mouse fibrosarcoid cells in Tumour Necrosis Factor-mediated cytotoxicity. Cancer Res 53: 1456–1460

  17. Leek RD, Landers R, Fox SB, NGF Harris AL and Lewis CE (1998) Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer 77: 2246–2251

  18. Lewis CE and McGee JO'D (1996) The role of TNF-alpha: implications for prognosis and possible strategies for intervention. Horizons in Medicine 7: 270–282

  19. Lewis CE and Balkwill FR (1997) The complex molecular network regulating tumour angiogenesis. In Tumour Angiogenesis, Bicknell R, Lewis CE, Ferrara N (eds), pp. 111–113, Oxford University Press: Oxford

  20. Lienard D, Lejeune FJ and Ewalenko P (1992) In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion. World J Surg 16: 234–240

  21. Liotta LA and Stetler-Stevenson WG (1991) Tumour invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 51: 5054–5059

  22. Lippman ME, Dickson RB, Gelmann EP, Rosen N, Knabbe C, Bates S, Bronzert D, Huff KE and Kasid A (1987) Growth regulation of human breast carcinoma occurs through regulated growth factor secretion. J Cell Biochem 35: 1–16

  23. McCune BK, Mullin BR, Flanders KC, Jaffers WS, Mullen LT and Sporn MB (1992) Localisation of transforming growth factor-beta isotypes in lesions of the human breast. Hum Pathol 23: 13–20

  24. Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD and Balkwill FR (1994) Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int J Cancer 56: 777–782

  25. Mizukami Y, Nonomura A, Yamada T, Kurumaya H, Hayashi M, Koyasaki N, Taniya T, Nonguchi M, Nakamura S and Matsubara F (1990) Immunohistochemical demonstration of growth factors TGF alpha, TGF beta, IFG-I and neu oncogene product in benign and malignant breast tissues. Anticancer Res 10: 1115–1126

  26. Munker M, Munker R, Saxton RS and Hoeffler HP (1987) Effect of recombinant monokines, lymphokines, and other agents on clonal proliferation of human cancer cell lines. Cancer Res 47: 4081–4085

  27. Murray PA, Barrett-Lee P, Travers M, Luqmani Y, Powels T and Coombes RC (1993) The prognostic significance of transforming growth factors in human breast cancer. Br J Cancer 67: 1408–1412

  28. Naylor MS, Stamp GW, Foulkes WD, Eccles D and Balkwill FR (1993) Tumour necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest 91: 2194–2206

  29. Ohkura M, Fuchimoto S and Orita K (1990) Antitumour effect of recombinant human interleukin-1 beta alone and in combination with natural tumour necrosis factor-alpha. Jpn J Cancer Res 81: 1026–1031

  30. Pezzella F, Jones M, Ralfkier E, Ersbol J, Gatter KC and Mason DJ (1992) Evaluation of bcl2 protein expression and 14;18 translocation as prognostic markers in follicular lymphoma. Br J Cancer 65: 87–89

  31. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC and Mason DY (1993) Bcl-2 protein in non small-cell lung carcinoma. New Engl J Med 329: 690–694

  32. Pusztai L, Clover LM, Cooper K, Starkey PM, Lewis CE and McGee JO'D (1994) Expression of tumour necrosis factor alpha and its receptors in carcinoma of the breast. Br J Cancer 70: 289–292

  33. Rubbert A, Manger B, Lang N, Kalden JR and Platzer E (1991) Functional characterization of tumour-infiltrating lymphocytes, lymphonode lymphocytes, and peripheral lymphocytes. Int J Cancer 49: 25–31

  34. Silvestrini R, Costa A, Lequaglie C, Mochen C, Veneroni S, Leutner M and Ravasi G (1998) Bcl-2 protein and prognosis in patients with potentially curable non-small-cell lung cancer. Virchows Arch 432: 441–444

  35. Schiller JH and Bittner G (1990) Anti-proliferative effects of tumour necrosis factor, gamma interferon, and 5-fluorouracil on human colorectal carcinoma cell lines. Int J Cancer 46: 61–66

  36. Sporn MB, Roberts AB, Wakefield LM and Assoian RK (1986) Transforming growth factor beta: biological function and chemical structure. Science 233: 532–534

  37. Tran T-A, Kallakury BVS, Ambros RA and Ross JS (1998) Prognostic significance of tumour necrosis factors and their receptors in nonsmall cell lung carcinoma. Cancer 83: 276–282

  38. Ueki N, Nakazato M, Ohkawa T, Ikeda T, Amuro Y, Hada T and Higashino K (1992) Excessive production of TGFβ1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumour growth. Biochem Biophys Acta 1137: 189–196

  39. Walker RA and Dearing SJ (1992) Transforming growth factor beta1in ductal carcinoma in situ and invasive carcinomas of the breast. Eur J Cancer 28: 641–644

  40. World Health Organization (1982) The World Health Organization histological typing of lung tumours. Am J Clin Pathol 77: 123–136

  41. Yang SC, Owen-Schaub LB, Grimm EA and Roth JA (1989) Induction of lymphokine-activated killer cytotoxicity with interleukin-2 and tumour necrosis factor-alpha against primary lung cancer targets. Cancer Immunol Immunother 29: 193–198

Download references

Author information

Rights and permissions

From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Reprints and Permissions

About this article

Cite this article

Boldrini, L., Calcinai, A., Samaritani, E. et al. Tumour necrosis factor- α and transforming growth factor- β are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization. Br J Cancer 83, 480–486 (2000). https://doi.org/10.1054/bjoc.2000.1345

Download citation

Keywords

  • NSCLC
  • tumour necrosis factor alpha
  • transforming growth factor beta
  • angiogenesis
  • prognosis

Further reading